RTx-015 / Ray Therap - LARVOL DELTA

Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION) (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Ray Therapeutics, Inc. | Trial completion date: May 2026 ➔ Oct 2030 | Trial primary completion date: May 2026 ➔ Oct 2030

Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Ray Therapeutics Awarded $8M CIRM Grant to Advance RTx-015 Gene Therapy for Retinitis Pigmentosa (Businesswire) - "Ray Therapeutics...today announced it has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM). The grant will support the company’s ongoing clinical development of RTx-015 for the treatment of retinitis pigmentosa (RP), a progressive and debilitating inherited retinal disease that leads to blindness."

Financing • Retinitis Pigmentosa

Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa Patients (ENVISION) (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Ray Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa Patients (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Ray Therapeutics, Inc.

New P1 trial • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa